Drug
Napabucasin clinical trials
Also written BBI608 and BB608.
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 2
Sumitomo Pharma America, Inc. (11) · Sumitomo Pharma Co., Ltd. (3) · NCIC Clinical Trials Group (1) · Australasian Gastro-Intestinal Trials Group (1)
Often tested with
Tested in the same studies.
Amcasertib (2) · Paclitaxel (1) · Temozolomide (1) · Bevacizumab (1) · Pemetrexed (1) · Cisplatin (1) · Sorafenib (1) · BNC 105 (1)
Studies
Open first, then newest update. How each study uses napabucasin is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaCompletedPhase 3Sumitomo Pharma America, Inc.NCT02993731Written as Napabucasin
- A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedPhase 3Sumitomo Pharma America, Inc.NCT02753127Written as Napabucasin
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced MalignanciesCompletedPhase 1/2Sumitomo Pharma America, Inc.NCT01325441Written as BBI608
- A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed GlioblastomaCompletedPhase 1/2Sumitomo Pharma America, Inc.NCT02315534Written as BBI608
- A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular CarcinomaCompletedPhase 1/2Sumitomo Pharma America, Inc.NCT02279719Written as BBI608
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedPhase 3Sumitomo Pharma America, Inc.NCT02178956Written as BBI608
- A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung CancerTerminatedPhase 3Sumitomo Pharma America, Inc.NCT02826161Written as Napabucasin
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy VolunteersCompletedPhase 1Sumitomo Pharma America, Inc.NCT03411122Written as napabucasin
- A Study of BBI608 in Adult Patients With Advanced MalignanciesCompletedPhase 1Sumitomo Pharma America, Inc.NCT01775423Written as BBI608
- A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid TumorsCompletedPhase 1Sumitomo Pharma America, Inc.NCT02432326Written as BBI608
- A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male SubjectsCompletedPhase 1Sumitomo Pharma America, Inc.NCT03525405Written as napabucasin
- BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal CarcinomaCompletedPhase 3NCIC Clinical Trials GroupNCT01830621Written as BBI608
- A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal CancerCompletedPhase 1Sumitomo Pharma Co., Ltd.NCT02641873Written as BBI608
- A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural MesotheliomaCompletedPhase 1/2Sumitomo Pharma Co., Ltd.NCT02347917Written as BBI608
- A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular CarcinomaCompletedPhase 1Sumitomo Pharma Co., Ltd.NCT02358395Written as BBI608
- Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerCompletedPhase 2Australasian Gastro-Intestinal Trials GroupNCT03647839Written as BBI608
Given in every arm · 8 — napabucasin is usual care beside what is tested
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic CancerCompletedPhase 1Sumitomo Pharma America, Inc.NCT02231723Written as BBI608
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal CancerCompletedPhase 1/2Sumitomo Pharma America, Inc.NCT02024607Written as BBI608
- A Study of BBI608 in Adult Patients With Advanced Colorectal CancerCompletedPhase 2Sumitomo Pharma America, Inc.NCT01776307Written as BBI608
- A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic MalignanciesCompletedPhase 1Sumitomo Pharma America, Inc.NCT02352558Written as BBI608
- A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced CancersCompletedPhase 1Sumitomo Pharma America, Inc.NCT02467361Written as BBI608
- Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsCompletedPhase 1Sumitomo Pharma America, Inc.NCT04299880Written as Napabucasin
- Special Combination of BBI608 and PembrolizumabTerminatedPhase 1/2Takayuki YoshinoNCT02851004Written as Napabucasin
- A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal CancerStatus unknownPhase 31Globe Health Institute LLCNCT03522649Written as Napabucasin
Codes
What other systems call napabucasin · ClinicalTrials.gg INT000728
- UNII (FDA) Z1HHM49K7ONAPABUCASINConfirmed FDA, Wikidata
- Wikidata Q27294876napabucasinConfirmed FDA, Wikidata
- NCI Thesaurus C96429NapabucasinOne source FDA
- DrugBank DB12155One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z1HHM49K7O | NAPABUCASIN | Confirmed FDA, Wikidata |
| Wikidata | Q27294876 | napabucasin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C96429 | Napabucasin | One source FDA |
| DrugBank | DB12155 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.